Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Phase 3

Not yet recruiting

Conditions: Gastric Carcinoma

Interventions: Drug: Apatinib
Drug: XELOX

First Posted Date: 2017-11-28

Last Posted Date: 2017-11-28

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 456

Registration Number: NCT03355612

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Not Applicable

Terminated

Conditions: Peritoneal Metastases From Gastric Cancer

Interventions: Procedure: exploratory laparoscopy or laparotomy
Procedure: HIPEC
Drug: Systemic chemotherapy
Drug: Apatinib

First Posted Date: 2017-11-22

Last Posted Date: 2020-03-24

Lead Sponsor: Wuhan University

Target Recruit Count: 20

Registration Number: NCT03349827

Locations: 🇨🇳
Wuhan University, Wuhan, Hubei, China

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Phase 2

Conditions: Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: apatinib
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Radiotherapy

First Posted Date: 2017-11-22

Last Posted Date: 2020-02-19

Lead Sponsor: Hebei Medical University

Target Recruit Count: 48

Registration Number: NCT03349866

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, ShiJiaZhuang, Hebei, China

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Apatinib
Drug: Paclitaxel

First Posted Date: 2017-11-20

Last Posted Date: 2017-11-28

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT03348098

Locations: 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China

Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Phase 2

Conditions: Two Different Treatment Methods

Interventions: Drug: Apatinib

First Posted Date: 2017-11-07

Last Posted Date: 2017-11-14

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 60

Registration Number: NCT03334591

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Phase 2

Conditions: Thyroid Cancer

Interventions: Drug: Apatinib
Radiation: Intensity modulated radiation therapy

First Posted Date: 2017-10-03

Last Posted Date: 2017-10-03

Lead Sponsor: Xiayun He, MD

Target Recruit Count: 20

Registration Number: NCT03300765

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Etoposide
Drug: Apatinib

First Posted Date: 2017-09-29

Last Posted Date: 2017-09-29

Lead Sponsor: Yang Zhijun

Target Recruit Count: 60

Registration Number: NCT03298074

An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Phase 2

Conditions: Esophagus Cancer, Stage III
Esophageal Gastric Cardia Type Metaplasia
Esophagus Cancer, Stage IV

Interventions: Drug: Apatinib

First Posted Date: 2017-09-18

Last Posted Date: 2017-09-18

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT03285906

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Esophageal Neoplasms

Interventions: Drug: Apatinib

First Posted Date: 2017-09-06

Last Posted Date: 2021-01-26

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT03274011

Locations: 🇨🇳
Shanghai Yangpu District East Hospital, Shanghai, Shanghai, China

A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Apatinib

First Posted Date: 2017-09-01

Last Posted Date: 2017-09-01

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT03271073

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy